Last reviewed · How we verify
CCS1477
At a glance
| Generic name | CCS1477 |
|---|---|
| Sponsor | CellCentric Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies (PHASE1, PHASE2)
- Study to Evaluate CCS1477 in Advanced Tumours (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CCS1477 CI brief — competitive landscape report
- CCS1477 updates RSS · CI watch RSS
- CellCentric Ltd. portfolio CI